LONDON–(BUSINESS WIRE)–Regulatory News: BenevolentAI (Euronext Amsterdam: BAI) (“BenevolentAI” or the “Company” or the “Group”), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2023. Dr. François Nader, Chair and Acting CEO of BenevolentAI, said: “Since the Strategic Review in May we have made significant progress in executing our strategic plan including signing our new collaboration with Merck
Click here to view original post
Copyright © 2023 Biotech Networks, LLC
